About this trial
This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.
Eligibility criteria
Qualifiers
IPSS score > 20
Uroflowmetry flow rate < 10 ml/sec
Post-void residual > 150 cc
PSA level between 4 and 20 ng/ml
Disqualifiers
Patient PSA level > 20 ng/ml
More than 3 focal lesions on MP-MRI
Metastatic prostate cancer
History of lower urinary tract surgery (e.g., TURP, Laser, urinary diversions, artificial urinary sphincter)
Trial design
Treatments tested in this trial
- Bioblation